Showing 1 - 10 of 922
We describe the broad range of uncertainties faced by the developers of medical technologies. Empirically, we estimate the asset market incidence of two realizations of uncertainties we classify as within-market policy risks. The events we analyze concern the intellectual property of Myriad...
Persistent link: https://www.econbiz.de/10013017486
We estimate channels of international risk sharing between European Monetary Union (EMU), European Union, and other … OECD countries 1992-2007. We focus on risk sharing through savings, factor income flows, and capital gains. Risk sharing … through factor income and capital gains was close to zero before 1999 but has increased since then. Risk sharing from capital …
Persistent link: https://www.econbiz.de/10013118134
their risk assessments and outcomes to those from a simple methodology that relies on publicly available market data and … market data; (iii) This discrepancy arises due to the reliance on regulatory risk weights in determining required levels of … capital once stress-test losses are taken into account. In particular, the continued reliance on regulatory risk weights in …
Persistent link: https://www.econbiz.de/10013083085
trade policy risk across products and asymmetric for UK and EU exporters. We estimate that a persistent doubling of the …
Persistent link: https://www.econbiz.de/10012906789
Do intellectual property (IP) rights on existing technologies hinder subsequent innovation? Using newly-collected data on the sequencing of the human genome by the public Human Genome Project and the private firm Celera, this paper estimates the impact of Celera's gene-level IP on subsequent...
Persistent link: https://www.econbiz.de/10013069502
Increased global demand for biofuels is placing increased pressure on agricultural systems at a time when traditional sources of yield improvements have been mostly exhausted, generating concerns about the future of food prices. This paper estimates the impact of global adoption of genetically...
Persistent link: https://www.econbiz.de/10013038332
markets. We use data on individuals at risk for Huntington disease (HD), a degenerative neurological disorder with significant …
Persistent link: https://www.econbiz.de/10013156533
Pharmacogenomics, or the application of genetic testing to guide drug selection and/or dosing, is often cited as integral to the vision of how precision medicine can be integrated into routine clinical practice. Yet despite a growing base of scientific discovery on genetic variation that...
Persistent link: https://www.econbiz.de/10012941158
This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...
Persistent link: https://www.econbiz.de/10013311658
Profit on proprietary research tools is determined partly by the remedies for infringement, such as damages and injunctions. We investigate how damages under a liability rule and the opportunity for injunctions under a property rule can affect the incentives to develop research tools. We show...
Persistent link: https://www.econbiz.de/10013228234